MetaCap

Harrow (HROW) vs OPKO Health (OPK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OPKO Health (OPK) has outperformed Harrow (HROW) over the past year, gaining 18.9% versus a loss of 21.8%. Over five years, HROW leads with a +196.1% price change compared with -62.0% for OPK. OPKO Health is the larger company by market cap ($1.17 billion vs $1.14 billion), about 1.0 times the size, while Harrow is growing revenue faster (+36.4% vs -14.9%).

Harrow converts more of its revenue into profit, with a net margin of -1.9% versus -37.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HROW-21.85%OPK+18.94%
+45%+4%-37%
Nov 21, 20251 yearNov 20, 2026
HROW+181.31%OPK-63.91%
+457%+176%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HROW versus OPK key metrics
MetricHROWOPK
Share price$30.41$1.57
Market cap$1.14B$1.17B
1-day change-5.35%-2.48%
YTD return-37.94%+24.60%
1-year return-21.85%+18.94%
5-year return+196.11%-61.99%
Forward P/E16.26—
EPS (TTM)$-0.76$-0.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$272.30M$606.88M
Revenue growth (YoY)+36.41%-14.90%
Net income (latest FY)$-5.14M$-225.68M
Gross margin75.05%33.93%
Operating margin11.21%-19.35%
Net margin-1.89%-37.19%
52-week high$54.85$1.86
52-week low$25.76$0.98
Distance from 52-week high-44.56%-15.59%
Analyst consensusstrong_buybuy
Avg. price target upside+104.70%+164.33%
Average volume626.20K3.83M
Shares outstanding37.53M742.51M
Employees3732,275
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OPK has outperformed HROW by 40.8 percentage points over the past year.
  • Harrow is more profitable, keeping -1.9 cents of every revenue dollar as net income versus -37.2 cents for OPKO Health.
  • Harrow grew revenue faster in its latest fiscal year (+36.41% vs -14.90%).

About Harrow

HROW stock →

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees

About OPKO Health

OPK stock →

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,275 employees

HROW vs OPK FAQ

Which is bigger, Harrow or OPKO Health?

OPKO Health (OPK) is larger, with a market capitalization of $1.17B compared with $1.14B for Harrow (HROW).

Which stock has performed better over the past year, HROW or OPK?

OPK returned +18.94% over the past 12 months, compared with -21.85% for HROW (price return, excluding dividends). Past performance does not predict future results.

Are Harrow and OPKO Health in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons